Antihemophilic medicines, biosurgery products and injectable drugs also boosted sales. Overall second-quarter revenue surged 16% to $4.3 billion, compared with $3.7 billion the year prior.
Baxter's net income dropped 12% to $520 million, representing a 12% profit margin. Several one-time charges—like costs related to its Gambro purchase and a recall of some of its infusion pumps—dragged earnings down. Baxter also has started accruing charges related to its plan to split into two companies.
In March, Baxter announced it would splinter into a biopharmaceuticals company and a medical-device company, similar to what competitor Abbott Laboratories has done. Baxter Chairman and CEO Robert Parkinson Jr. said the company is on track to separate by mid-2015.
Adjusted for those one-time expenses in both periods, Baxter's profit increased 5%.
For the six months ended June 30, Baxter's profit dropped 6% to a little less than $1.1 billion. Revenue jumped 15% to $8.2 billion.
The company confirmed its outlook for the rest of the year, saying adjusted earnings per diluted share would be between $5.10 and $5.20.
Follow Bob Herman on Twitter: @MHbherman